Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recce 327 gel
- Development stage
- Unknown
- Lead developer
- Recce Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
RECCE 327 Gel is a topical formulation of RECCE 327, a synthetic polymer anti-infective being developed by Recce Pharmaceuticals. It represents one of the first new classes of antibiotics in over 30 years with a universal mechanism of action that allows it to continuously kill bacteria and multi-drug resistant superbugs. The gel formulation is primarily being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot infections (DFI).
- Brand names
- R327GR-327GR 327G
- Other names
- RECCE 327 Topical GelRECCE327 Topical GelRECCE-327 Topical Gel
02
Targets
Bacterial membrane protein
Beyond the preview
Go deeper on recce 327 gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recce 327 gel.